# PHLDA3

## Overview
PHLDA3, or Pleckstrin Homology Like Domain Family A Member 3, is a gene that encodes a small protein characterized by the presence of a pleckstrin homology (PH) domain. This domain is crucial for the protein's function as it facilitates binding to phosphatidylinositol phosphates (PIPs), thereby localizing the protein to the cellular membrane. The PHLDA3 protein acts as a negative regulator of the Akt signaling pathway, a critical pathway for cell survival and growth, by competitively inhibiting Akt's binding to membrane lipids. This inhibition is significant for inducing apoptosis, particularly in response to DNA damage, as PHLDA3 is a p53-inducible protein. The gene's role in tumor suppression is underscored by its involvement in various cancers, where its expression is often downregulated, leading to enhanced Akt activity and tumor progression (Kawase2009PH; Ma2021PHLDA3).

## Structure
PHLDA3 is a small protein consisting of 127 amino acids, primarily characterized by the presence of a Pleckstrin Homology (PH) domain. This domain is highly conserved among vertebrates and is essential for the protein's function. The PH domain facilitates binding to phosphatidylinositol phosphates (PIPs), which localizes PHLDA3 to the cellular membrane, a critical step for its role in inducing apoptosis (Kawase2009PH). The PH domain of PHLDA3 is similar to that of Akt, a serine/threonine kinase, and is involved in competitive inhibition of Akt by preventing its binding to membrane lipids, thereby inhibiting Akt's translocation and activation (Kawase2009PH).

PHLDA3 is a p53-inducible protein, meaning its expression is regulated by the tumor suppressor protein p53, particularly in response to DNA damage (Kawase2009PH). The protein does not have any known splice variant isoforms mentioned in the context. While the context does not provide specific details on the secondary, tertiary, or quaternary structures of PHLDA3, the PH domain's role in membrane association and protein-protein interactions is emphasized as a key structural and functional feature (Liu2019Novel).

## Function
PHLDA3 is a p53-regulated protein that functions as a repressor of the Akt signaling pathway, which is crucial for cell survival and growth. It plays a significant role in inducing apoptosis, a process of programmed cell death, by inhibiting Akt activity. This inhibition is achieved through the competitive binding of PHLDA3's pleckstrin homology (PH) domain to phosphatidylinositol phosphates (PIPs), preventing Akt's translocation to the plasma membrane and its subsequent activation (Kawase2009PH). 

PHLDA3 is essential for p53-dependent apoptosis, as its expression is necessary for the full apoptotic response to DNA damage in cells (Kawase2009PH). It acts as a dominant-negative molecule for other PH domain-containing proteins, such as Akt, by shutting off their signal transduction pathways, thereby promoting apoptosis (Kawase2009PH). 

In healthy human cells, PHLDA3's activity is primarily localized to the cellular membrane, where it exerts its function in apoptosis induction. Its role in repressing Akt activity is specific and does not affect other pathways like Erk, highlighting its selective involvement in cell signaling (Kawase2009PH).

## Clinical Significance
PHLDA3 is implicated in various cancers due to its role as a tumor suppressor gene. In prostate cancer, PHLDA3 expression is significantly reduced, correlating with decreased patient survival. This down-regulation is linked to promoter hypermethylation, and restoring PHLDA3 expression can inhibit cell proliferation and enhance sensitivity to chemotherapy (Ma2021PHLDA3). In neuroendocrine tumors, particularly pancreatic and lung NETs, PHLDA3 acts as a repressor of the Akt pathway. Its loss, often through loss of heterozygosity and methylation, leads to increased Akt activation, contributing to tumor progression and poor prognosis (Chen2020p53PHLDA3Akt; Takikawa2017A).

PHLDA3 is also involved in the crosstalk between the PI3K/AKT pathway and PPP metabolism, where its expression is inhibited by PPP metabolites, promoting AKT activation and cancer cell survival. This suggests that PHLDA3 alterations could contribute to treatment resistance in cancers with PI3K activation (Cheng2020TRIM21). The gene's frequent loss in lung endocrine tumors, particularly large-cell neuroendocrine carcinoma, underscores its significance in tumor suppression (Kawase2009PH). These findings highlight PHLDA3 as a potential biomarker and therapeutic target in various cancers.

## Interactions
PHLDA3, a p53-regulated gene, encodes a protein that interacts with several key proteins and pathways, primarily acting as a negative regulator of the Akt signaling pathway. PHLDA3 inhibits Akt activation by competing with phosphoinositides PI(3,4)P2 and PI(3,4,5)P3 for binding, thereby preventing Akt's translocation to the membrane and subsequent activation (Kawase2009PH; don2015role). This interaction is crucial for its role in inducing apoptosis and inhibiting cell survival pathways.

PHLDA3 also interacts with DJ-1, a protein involved in neuroprotection. DJ-1 binds to PHLDA3, potentially sequestering it from the membrane and modulating its inhibitory effect on Akt. This interaction is significant in the context of oxidative stress, where DJ-1's presence reduces PHLDA3-induced neuronal death by facilitating Akt activation (don2015role).

In the context of cancer, PHLDA3's interaction with the Wnt/β-catenin signaling pathway has been noted. Overexpression of PHLDA3 leads to decreased Akt phosphorylation, which in turn suppresses the Wnt/β-catenin pathway, highlighting its role in tumor suppression (Ma2021PHLDA3). These interactions underscore PHLDA3's multifaceted role in cellular stress responses and tumor suppression.


## References


[1. (Liu2019Novel) Jia Liu, Xiaoxiong Liu, Xuejun Hui, Lin Cai, Xuebo Li, Yang Yang, Shangzhi Shu, Fan Wang, Hao Xia, and Shuyan Li. Novel role for pleckstrin homology‐like domain family a, member 3 in the regulation of pathological cardiac hypertrophy. Journal of the American Heart Association, August 2019. URL: http://dx.doi.org/10.1161/JAHA.118.011830, doi:10.1161/jaha.118.011830. This article has 19 citations.](https://doi.org/10.1161/JAHA.118.011830)

2. (don2015role) Katherine Don-Carolis. Role of DJ-1 in the Activation of AKT Via Binding and Inhibition of PHLDA3 Under Oxidative Stress. PhD thesis, Université d'Ottawa/University of Ottawa, 2015. This article has 0 citations.

[3. (Chen2020p53PHLDA3Akt) Yu Chen and Rieko Ohki. P53-phlda3-akt network: the key regulators of neuroendocrine tumorigenesis. International Journal of Molecular Sciences, 21(11):4098, June 2020. URL: http://dx.doi.org/10.3390/ijms21114098, doi:10.3390/ijms21114098. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms21114098)

[4. (Kawase2009PH) Tatsuya Kawase, Rieko Ohki, Tatsuhiro Shibata, Shuichi Tsutsumi, Naoko Kamimura, Johji Inazawa, Tsutomu Ohta, Hitoshi Ichikawa, Hiroyuki Aburatani, Fumio Tashiro, and Yoichi Taya. Ph domain-only protein phlda3 is a p53-regulated repressor of akt. Cell, 136(3):535–550, February 2009. URL: http://dx.doi.org/10.1016/j.cell.2008.12.002, doi:10.1016/j.cell.2008.12.002. This article has 195 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cell.2008.12.002)

[5. (Ma2021PHLDA3) Shuaijun Ma, Penghe Quan, Changjiang Yu, Xiaozheng Fan, Shuhan Yang, Weijing Jia, Longlong Zhang, Fuli Wang, Fei Liu, Lijun Yang, Weijun Qin, and Xiaojian Yang. Phlda3 exerts an antitumor function in prostate cancer by down-regulating wnt/β-catenin pathway via inhibition of akt. Biochemical and Biophysical Research Communications, 571:66–73, September 2021. URL: http://dx.doi.org/10.1016/j.bbrc.2021.07.038, doi:10.1016/j.bbrc.2021.07.038. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2021.07.038)

[6. (Cheng2020TRIM21) Jie Cheng, Yan Huang, Xiaohui Zhang, Yue Yu, Shumin Wu, Jing Jiao, Linh Tran, Wanru Zhang, Ran Liu, Liuzhen Zhang, Mei Wang, Mengyao Wang, Wenyu Yan, Yilin Wu, Fangtao Chi, Peng Jiang, Xinxiang Zhang, and Hong Wu. Trim21 and phlda3 negatively regulate the crosstalk between the pi3k/akt pathway and ppp metabolism. Nature Communications, April 2020. URL: http://dx.doi.org/10.1038/s41467-020-15819-3, doi:10.1038/s41467-020-15819-3. This article has 74 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-020-15819-3)

[7. (Takikawa2017A) Masahiro Takikawa and Rieko Ohki. A vicious partnership between <scp>akt</scp> and <scp>phlda</scp>3 to facilitate neuroendocrine tumors. Cancer Science, 108(6):1101–1108, May 2017. URL: http://dx.doi.org/10.1111/cas.13235, doi:10.1111/cas.13235. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/cas.13235)